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Clinical Presentation of Malaria
Usually characterized by fever with rigors but may mimic other viral infections like influenza, hepatitis
and bacterial infections such as respiratory and urinary infections. However, clinical assessment, is the
only feasible approach to the diagnosis of malaria. Laboratory confirmation has a limited role.
The clinical diangosis of malaria is defined on the presence, or recent history of fever, after exclusion
of other major causes of fever1,2. The exclusion of other causes of fever may be difficult. But in a high
malaria risk area, WHO guidelines recommend treatment with antimalarial drugs for any febrile child.
In low risk malarious areas, malaria is considered in a febrile patient after giving thought to other
conditions such as URTI, UTI and others. If any of these latter conditions is observed, the child is first
treated for these conditions and if no improvement occurs within 2 days, the patient is treated for
malaria2.
Evaluation
A basic clinical examination is required to identify persons with signs of severe malaria. The
examination should include an assessment of:
* Central nervous system function - presence or history of convulsions and an assessment of the
patient’s mental status.
* Presence of respiratory distress
* Hydration status/Vom itting
* Presence of Hyperpyrexia
* Presence of anemia.
A history of prior anti-malarial therapy should always be obtained for the current illness and whether
the patient is able to take oral medication or not.
The primary purpose of anti-malarial therapy is to ensure prompt, effective and safe treatment of
malaria. It could be either clinical cure or radical cure.
Chemotherapy of malaria
There is insufficient evidence to declare the whole of Pakistan as being chioroquine resistant P.
Falciparum (CRF), though it has only been documented in Punjab and the Northern Areas1,2. Other
species (vivax, ovale and malariae) are considered chioroquine sensitive. However, vigilance should be
kept up to detect resistance in this species as well. It is recommended that the uncomplicated case be
treated with chioroquine except in areas of resistance. In CRF - declared areas the second line drugs
may be used. Indiscriminate use of the newer anti-malarials should be avoided as this might lead to
drug resistance. All severe, complicated cases suspected or confinned should be referred to a hospital as
early as possible and treatment started immediately with intravenous quinine.
Mefloquine 250 mg every week (duration as for chloroquine)
Travellers are advised to carry chloroquine, sulfa/pyrimethamine combinations, mefloquine, quinine as
stand-by treatments, depending on the drug resistance status of the parasites in the areas to be visited.
Halofantrine is no longer recommended following reports that it can result in prolongation of QT
intervals and of ventricular dysrhythmias in susceptible individuals.
Travellers must check with Family Physicians! General Practitioners about chloroquine sensitive or
resistant areas.
Malaria in pregnancy
Malaria especially that caused by Plasmodium falciparum is often severe in pregnant patients and

carries a high risk of mortality to the foetus. Foetal distress commonly goes undiagnosed in this
situation.
There is an increased risk of premature labour, still births and abortions occurring due to the malaria
hyperpyrexia and the use of some anti-malarial drugs with abortifacient effects but mainly due to the
intrinsic disease itself.
Occasionally in non-immune mothers the malarial parasites may cross the placenta initiating fetal
infection. Congential malaria results in intra-uterine growth retardation. Infected neonates have
seizures, jaundice, hepatomegaly and often pulmonary edema.
Malaria caused by P. Vivax, P. Ovale and non chioroquine resistant P. Falciparum are treated with
chloroquine phosphate as per standard therapy. If Primaquine phosphate is prescribed the fetus is at risk
of intra-vascular hemolysis because fetal RBCs are relatively deficient in G6PD and glutath lone. Both
pyrimethamine and Fansidar are teratogenic and their risk has to be weighted against their benefits to
the mother.
In summary malaria in pregnancy causes significant maternal and fetal morbidity and fetal mortality.
Its treatment should be cautiously selected in consideration of the abortifacient properties and
teratogenicity of some of the anti-malarial drugs mentioned. Non-immune mothers
should be discouraged from travelling to endemic areas, as safe therapy for chioroquine resistant
plasmodium falciparum is not available for pregnant patients.
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